- Conditions
- Postpartum Depression
- Interventions
- Placebo, SAGE-547 60 μg/kg/h, SAGE-547 90 μg/kg/h
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 27 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–22
of 22
matching trials from the live ClinicalTrials.gov search.
- Conditions
- PTSD, Alcohol Use Disorder
- Interventions
- Brexanolone
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Matching IV Placebo, Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm
- Behavioral · Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Postpartum Depression
- Interventions
- Placebo, SAGE-547 90 μg/kg/h
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more
- Conditions
- Fragile X-associated Tremor/Ataxia Syndrome
- Interventions
- Allopregnanolone
- Drug
- Lead sponsor
- Randi J. Hagerman, MD
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Postpartum Depression
- Interventions
- ZULRESSO®
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Culver City, California • Miramar, Florida • Pompano Beach, Florida + 2 more
- Conditions
- Postpartum Depression
- Interventions
- SAGE-547
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Super-Refractory Status Epilepticus
- Interventions
- SAGE-547, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 76 more
- Conditions
- Postpartum Psychosis
- Interventions
- Brexanolone
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Post Partum Depression
- Interventions
- Brexanolone
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 15 Years to 17 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 17
- States / cities
- Tempe, Arizona • North Little Rock, Arkansas • Miramar, Florida + 14 more
- Conditions
- Postpartum Depression
- Interventions
- Brexanolone
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Severe Postpartum Depression
- Interventions
- SAGE-547, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Worcester, Massachusetts • Chapel Hill, North Carolina + 1 more
- Conditions
- Post-Traumatic Stress Disorder
- Interventions
- Brexanolone Injection [Zulresso]
- Drug
- Lead sponsor
- Donald Jeffrey Newport
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Super-refractory Status Epilepticus
- Interventions
- SAGE-547
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Sarasota, Florida • Chicago, Illinois + 13 more
- Conditions
- Pharmacokinetic Study, Post Traumatic Stress Disorder
- Interventions
- PK-1 Good Manufacturing Practices (GMP) allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis, PK-2 GMP allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis.
- Drug
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pregnant Women, Psychotropic Drugs
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2033
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression, Post-Natal Depression, Peripartum Depression
- Interventions
- LPCN 1154A, Placebo
- Drug
- Lead sponsor
- Lipocine Inc.
- Industry
- Eligibility
- 15 Years to 45 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Canoga Park, California • Walnut Creek, California + 13 more
- Conditions
- Depression
- Interventions
- brexanolone, placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years to 60 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Tinnitus
- Interventions
- Brexanolone
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Iowa City, Iowa
- Conditions
- Essential Tremor
- Interventions
- SAGE-547, Placebo
- Drug
- Lead sponsor
- Sage Therapeutics
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Bingham Farms, Michigan • Raleigh, North Carolina
- Conditions
- Acute Respiratory Distress Syndrome, COVID-19
- Interventions
- Brexanolone, Placebo
- Drug
- Lead sponsor
- Sage Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- Fresno, California • Augusta, Georgia • Boston, Massachusetts + 6 more
- Conditions
- Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD), Post-Natal Depression, Peripartum Depression, Postnatal Depression
- Interventions
- LPCN 1154A, Placebo
- Drug
- Lead sponsor
- Lipocine Inc.
- Industry
- Eligibility
- 15 Years to 45 Years · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 18
- States / cities
- Anahiem, California • Canoga Park, California • Miami, Florida + 14 more